TRCT
STOK icon

Tower Research Capital (TRC)’s Stoke Therapeutics STOK Stock Holding History

Tower Research Capital (TRC)’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$144K Buy
4,427
+3,797
+603% +$125K ﹤0.01% 1888
2025
Q4 		$20K Sell
630
-530
-46% -$15.9K ﹤0.01% 3101
2025
Q3 		$27.3K Sell
1,160
-3,210
-73% -$55K ﹤0.01% 3035
2025
Q2 		$49.6K Buy
4,370
+3,591
+461% +$34.1K ﹤0.01% 2977
2025
Q1 		$5.18K Sell
779
-11,151
-93% -$104K ﹤0.01% 4146
2024
Q4 		$132K Buy
11,930
+4,918
+70% +$60.4K ﹤0.01% 1996
2024
Q3 		$86.2K Buy
7,012
+2,994
+75% +$42.4K ﹤0.01% 2339
2024
Q2 		$54.3K Buy
4,018
+1,357
+51% +$18.3K ﹤0.01% 3040
2024
Q1 		$35.9K Sell
2,661
-2,378
-47% -$14.4K ﹤0.01% 2501
2023
Q4 		$26.5K Buy
5,039
+1,298
+35% +$5.55K ﹤0.01% 3489
2023
Q3 		$14.7K Sell
3,741
-942
-20% -$6.19K ﹤0.01% 3660
2023
Q2 		$49.8K Buy
4,683
+390
+9% +$4.15K ﹤0.01% 2589
2023
Q1 		$36K Sell
4,293
-30,200
-88% -$272K ﹤0.01% 2817
2022
Q4 		$319K Buy
34,493
+31,094
+915% +$323K 0.01% 975
2022
Q3 		$44K Sell
3,399
-1,376
-29% -$21.9K ﹤0.01% 3289
2022
Q2 		$63K Sell
4,775
-4,285
-47% -$65.1K ﹤0.01% 2675
2022
Q1 		$190K Buy
9,060
+5,925
+189% +$119K ﹤0.01% 1766
2021
Q4 		$75K Buy
3,135
+1,569
+100% +$37.4K ﹤0.01% 2440
2021
Q3 		$40K Sell
1,566
-5,969
-79% -$166K ﹤0.01% 3132
2021
Q2 		$254K Buy
7,535
+5,982
+385% +$211K 0.01% 1745
2021
Q1 		$60K Sell
1,553
-446
-22% -$25.4K ﹤0.01% 2974
2020
Q4 		$124K Sell
1,999
-5,232
-72% -$240K ﹤0.01% 2147
2020
Q3 		$243K Buy
7,231
+2,527
+54% +$72.2K ﹤0.01% 2389
2020
Q2 		$112K Buy
+4,704
New +$112K ﹤0.01% 2359

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Tower Research Capital (TRC)'s STOK Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Stoke Therapeutics (STOK) stake by 603% in Q1 2026, buying an estimated $125K and bringing the position to 4,427 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #1888.

Tower Research Capital (TRC) first reported a position in STOK in Q2 2020 and has held it in 24 quarters since. The position peaked at $319K in Q4 2022. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Tower Research Capital (TRC) held 4,427 shares of Stoke Therapeutics worth $144K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,797 Stoke Therapeutics shares in Q1 2026, an estimated $125K.
  • Stoke Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1888 holding.
  • Tower Research Capital (TRC) first reported a position in Stoke Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Stoke Therapeutics position peaked at $319K in Q4 2022.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.